
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **KRT6A, KRT14, KRT17, KRT6B, KRT5**: These are keratins, which are structural proteins typically expressed in epithelial cells. They play a role in the structural integrity and function of epithelial tissues.<br>- **ASF1B, UBE2C, PCLAF, CDK1, BIRC5, TYMS, STMN1, CKS1B, PTTG1**: These are associated with cell cycle regulation and proliferation. They are often upregulated in rapidly dividing cells, such as cancer cells.<br>- **DDIT4, GADD45A, PMAIP1**: Involved in stress response and apoptosis regulation.<br>- **SAA1, SERPINB5, SLPI, WFDC2**: These are involved in immune response and protease inhibition, often associated with inflammation and cancer.<br>- **HMGB2, RHOV, TACSTD2, ID1, TFDP1**: Involved in transcription regulation and cell differentiation.<br>- **MT1X, CSTB, S100P**: Associated with metal ion binding and calcium signaling, often linked to cancer progression.<br>- **PHGDH, RHEB, LSR, TPM2, MAL2**: Involved in metabolic processes and cell signaling pathways.<br><br>### Step 2: List the Key Cell Type Markers<br>- **KRT6A, KRT14, KRT17, KRT5**: These keratins are typically markers of basal epithelial cells, often found in the basal layer of the epidermis and in certain types of breast epithelial cells.<br>- **SERPINB5 (Maspin)**: A marker often associated with myoepithelial cells in the breast.<br>- **SOX9**: A transcription factor involved in the development and differentiation of various cell types, including stem and progenitor cells in the mammary gland.<br><br>### Step 3: Cross-reference Known Databases<br>Using scRNA-seq databases such as the Human Cell Atlas and literature on breast cancer, we can cross-reference these markers:<br>- **Basal Epithelial Cells**: Known to express KRT5, KRT14, and KRT17.<br>- **Myoepithelial Cells**: Express SERPINB5 and are involved in the structural support of the mammary gland.<br>- **Cancer Stem Cells**: Often express markers like SOX9 and exhibit high proliferation markers such as CDK1 and BIRC5.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of keratins (KRT5, KRT14, KRT17) and proliferation markers, the most probable general cell type is **Basal Epithelial Cells**. These cells are known for their role in the structural integrity of the epithelium and are often implicated in breast cancer.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Basal-like Breast Cancer Cells**: Characterized by high expression of basal keratins and proliferation markers.<br>2. **Myoepithelial Cells**: Express SERPINB5 and are involved in the contractile function of the mammary gland.<br>3. **Cancer Stem-like Cells**: Express SOX9 and exhibit high proliferation, contributing to tumor growth and metastasis.<br><br>The most likely subtype based on the markers is **Basal-like Breast Cancer Cells**, given the high expression of basal keratins and proliferation markers.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of Basal-like Breast Cancer Cells. This conclusion is supported by the high expression of basal keratins (KRT5, KRT14, KRT17) and proliferation markers (CDK1, BIRC5), which are characteristic of basal epithelial cells and are commonly associated with aggressive breast cancer subtypes.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The key functional markers and cell type markers listed in the annotation are present in the provided marker list. <br>   - The markers KRT6A, KRT14, KRT17, KRT5, and SERPINB5 are correctly identified as markers for basal epithelial cells and myoepithelial cells, respectively.<br>   - Proliferation markers such as CDK1 and BIRC5, as well as SOX9, are also present in the marker list, supporting the identification of cancer stem-like cells.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation acknowledges the presence of multiple potential subtypes, including Basal-like Breast Cancer Cells, Myoepithelial Cells, and Cancer Stem-like Cells.<br>   - The presence of markers for these subtypes is supported by several high-ranking markers, indicating a potential mixed population. However, the annotation appropriately identifies Basal-like Breast Cancer Cells as the most probable subtype based on the dominance of basal keratins and proliferation markers.<br><br>Overall, the annotation is well-supported by the marker list and provides a logical conclusion based on the expression patterns observed.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Basal Epithelial Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Basal-like Breast Cancer Cells</li><li>Myoepithelial Cells</li><li>Cancer Stem-like Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the marker list and its implications for identifying cell types within the breast cancer dataset. The analysis correctly identifies key markers such as KRT6A, KRT14, KRT17, and KRT5, which are indicative of basal epithelial cells, a common feature in basal-like breast cancer. The inclusion of proliferation markers like CDK1 and BIRC5 further supports the identification of aggressive cancer subtypes, aligning with the characteristics of basal-like breast cancer cells.<br><br>The annotation also acknowledges the presence of myoepithelial cells through the identification of SERPINB5 and considers the potential for cancer stem-like cells with the presence of SOX9. This demonstrates a balanced consideration of multiple markers and subtypes, providing a comprehensive view of the cell populations present in the dataset.<br><br>However, while the annotation does a good job of identifying the main cell type and potential subtypes, it could benefit from a more detailed discussion of the rank and relative importance of each marker. For instance, the presence of markers like KRT6A and KRT14 at the top of the list should be emphasized more, as they are critical in defining the basal epithelial cell identity. Additionally, the annotation could explore the potential mixed cell population more thoroughly, given the diverse range of markers present.<br><br>Overall, the annotation is scientifically accurate and provides a well-rounded view of the cell types present, with a few areas for improvement in terms of marker rank consideration and mixed population analysis.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    